Investor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in iTeos Therapeutics, Inc. Sale - ITOS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy ?
Source: Globenewswire
Investigation Announcement: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of iTeos Therapeutics, Inc. to Concentra Biosciences, LLC.
Transaction Details: Shareholders of iTeos would receive $10.047 in cash per share, along with a contingent value right related to the company's net cash and product candidates.
Adequacy Concerns: KSF is assessing whether the proposed consideration adequately values iTeos and the process leading to this transaction.
Legal Rights Information: Interested parties can contact KSF for discussions regarding their legal rights related to the sale, emphasizing the urgency due to the tender offer structure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
